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INTRODUCTION 41
Comprehensive characterisation of human organs, and their constitutive cell types, is 42 required to fully understand biological processes and disease development; concepts 43 underlying large-scale tissue and cell profiling projects, such as the Human Protein Atlas 44 (Uhlen et al., 2015) and Human Cell Atlas (Regev et al., 2017) . RNAseq data from 45 unfractionated human normal and diseased tissue is freely accessible through online portals, 46 e.g. Genotype-tissue expression (GTEx) project (https://gtexportal.org) (Consortium, 2015) 47 and the Cancer Genome Atlas (https://cancergenome.nih.gov), but deciphering cell type-48 specific profiles in such mixed-cell 'bulk' data is difficult. Recent advances have facilitated 49 sequencing of discrete cell populations or individual cells, but practical and technical 50 challenges, such as sourcing of suitable material, occurrence of artefacts due to processing, 51 compromised read depth and financial constraints, limit the accessibility of such methods 52 (Beliakova-Bethell et al., 2014; Rizzetto et al., 2017; Saliba et al., 2014; Ziegenhain et al., 53 7 for both sets of corresponding reference transcripts i.e. EC: [CD34, CLEC14A, VWF] and 141 AC: [BMPR1B, AQP4, SOX9] (the 'differential correlation score') and (2) the 'enrichment 142 ranking', based on the correlation value with each set of reference transcripts (highest 143 correlation: rank=1) ( Figure S3B ). Threshold lines indicate the rank number below which 144 transcripts were classified as cell-type enriched. EC and AC-enriched transcripts 'crossed' on 145 the plot ( Figure S3 Bi, yellow points), whilst EC transcripts well separated from the enriched 146 gene profiles of the other cell types ( Figure S3 Bii and iii) . were also well separated ( Figure S3 Biv) . 31 transcripts fulfilled the necessary criteria to be 148 classified both as EC and AC enriched (Figure 2A , yellow points [plot as for Figure S3B , but 149 transcripts ranked below enriched classification threshold excluded]) (Table S3 , Tab 5). 150
However, the majority of transcripts in the EC-and AC-enriched lists were well separated by 151 differential correlation. We sourced data from a previously published study where human 152 brain tissue was sorted into cell populations prior to RNAseq (Zhang et al., 2016) ; for 153 transcripts that we identified as (i) AC-enriched only, (ii) AC and EC-enriched or (iii) EC-154 enriched only (Figure 2A : purple, yellow and green, respectively) expression profiles were 155 consistent with our classifications ( Figure 2B ). Based on these analyses, transcripts 156 classified as EC-or AC-enriched were excluded from the final list(s) if they fulfilled 157 enrichment criteria for both, or if they had higher correlation values with the other (non-158 corresponding) reference transcripts. 159
Identification of endothelial, astrocyte, oligodendrocyte and neuron-enriched genes 160
Following application of selection criteria (reference transcript correlation in GTEx, replication 161 in MAYO, FDR threshold, SMC/MG and dual enriched transcript exclusion) ( Figure S2 ), 166 162 genes were classified as EC-enriched, 351 were AC-enriched, 380 were OC-enriched and 163 2015 were NC-enriched (Table S2- Ontology (GO) and Reactome ('pathway') analysis (Ashburner et al., 2000) was performed 173 on the final list of EC-, AC-, OC-and NC-enriched transcripts. The most significant biological 174 process GO groups in the EC-enriched list were related to EC function, including 'vasculature 175 development' and 'angiogenesis' (p-values <3.8x10^17) and reactome pathways included 176 (Table S2 , 177
Tab 4). The most significant biological process GO groups in the AC-enriched list included 178 'regulation of signalling' and 'small molecule catabolic process' (p-values <1.4x10^10) and 179 reactome pathways included 'metabolism' and 'transport of small molecules' (p-values 180 <1.3x10^5) (Table S3 , Tab 4). The most significant biological process GO group in the OC-181 enriched list was 'myelination' (p-value <1.6x10^17) and the single reactome pathway 182 identified was 'transport of small molecules' (p-value <7.8x10^7) (Table S4 , Tab 4). The most 183 significant biological process GO groups in the NC-enriched list included 'nervous system 184 development' and 'trans-synaptic signalling' (p-values <2.2x10^32) and reactome pathways 185 included 'neuronal system' and 'neurotransmitter receptors and postsynaptic signal 186 transmission' (p-values <9.5x10^17) (Table S3 , Tab 4). Summary plots were generated using 187 REViGO (Supek et al., 2011) (Figure 3 ). 188
Comparison of results with single-cell or fractionated brain cell type RNAseq data 189
We compared the top 100 most enriched EC, AC, OC and NC transcripts from our 190 unfractionated (UF) RNAseq analysis, to existing single-cell sequencing (scRNAseq) of 191 human brain (H1) (Darmanis et al., 2015) and RNAseq of fractionated FACS sorted or 192 immuno-panned isolated cell populations from both human (H2) (Zhang et al., 2016) and 193 mouse (M1) brain (Zhang et al., 2014) 
Comparison of reference transcript-based and weighted correlation network analysis 208
A disadvantage of our analysis is its reliance on a pre-selected panel of only 3 cell type-209 enriched 'reference' transcripts, and thus, is subject to a possible input bias. To determine 210 the extent of this limitation, we analysed the same datasets using an alternative 'unbiased' 211 approach -weighted correlation network analysis ('WGCNA') (Langfelder and Horvath, 212 2008) ; where correlations were generated between each transcript and all others, and 213 transcripts with similar profiles were clustered together. Analysis of the GTEx and MAYO 214 datasets produced a total of 37 and 50 independent clusters, respectively (Table S6 , Tab 1, 215 annotated with arbitrary numbers). Test-OC and test-EC panels were used to identify 216 clusters representing these cell types (Table S6 , Tab 2) ( Figure S5 A and B, green/orange 217 boxes) and GO enrichment analysis of these clusters were consistent with OC or EC identify, 218 respectively ( Figure S5C ). The majority of genes classified as OC-or EC-enriched by the 219 reference transcript analysis were also classified as such by WGCNA ( Figure S5 for details. We compared EC and OC-enriched lists, generated using each method, to brain 222 cortex single cell RNAseq (Darmanis et al., 2015) [H1] and isolated brain cell type RNAseq 223 (Zhang et al., 2016) [H2] (see Figure 4 ). The majority of the OC-enriched genes identified by 224 10 the reference transcript or WGCNA, were correspondingly enriched in both the [H1] (ref. 
Reference transcript analysis can be used to profile disease-associated modifications 233
Our data from the analysis of normal cortex was used as a starting point for the identification 234 of cellular changes in malignant disease. We used the reference transcript analysis to study 235 disease-associated changes in the vasculature of glioblastoma multiforme (GBM) and lower 236 grade glioma (LGG), where cross-talk between EC and tumour cells promotes proliferation 237 and subsequent disease progression (Yan et al., 2017) . Expression tables for GBM (n=401) 238 and LGG (n=516) samples from the Cancer Genome Atlas (TCGA) were sourced from the 239 Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/). As in normal brain, EC 240 genes [CD34, CLEC14A, VWF] correlated highly in GBM ( Figure 5A ) and LGG ( Figure 5B ) 241 (corr. mean GBM 0.67, LGG 0.74), with EC restricted expression ( Figure 5A and B, upper left 242 images), indicating suitability as EC reference transcripts in these cohorts. GBM and LGG 243 datasets were analysed as for normal brain (GTEx) ( Table S7 , Tab 1) to identify EC-enriched 244 transcripts. WGCNA of GBM RNAseq produced 2 clusters which contained EC markers 245 (n=104 and n=35) (Supplemental Figure 6A ). These clusters contained 78/85 (92%) of genes 246 classified as GBM EC-enriched by the reference transcript analysis (Supplemental Figure  247 6B) (Table S7 , Tab 2). We compared GBM and normal brain, using the differential correlation 248 score and enrichment rank of all transcripts categorised as EC-enriched in GBM or normal 249 brain ( Figure 5C ). 33 transcripts were EC-enriched in normal brain and GBM ( Figure 6C , 250 blue data points) (Table S7 , Tab 3). Of these, we previously identified 29/33 (88%) as body-251 wide core EC-enriched (Butler et al., 2016) , including ENG, TIE1, ESAM, CDH5 and ERG 252 11 (which encodes for a key transcription factor in the maintenance of EC-identify (Shah et al., 253 2016)); thus, this group likely represents genes indispensable for vascular function. A panel 254 of genes were EC-enriched in GBM, but not in normal brain, including PLXDC1, ACE, 255 PCDH12, and vice versa, including PAQR5, ANXA3, FAM111A ( Figure 6C , red and green 256 data points, respectively) (Table S7, Tab 3). LGG had a higher proportion of EC-enriched 257 genes in common with normal brain, compared to GBM ( Figure 5D -more blue data points 258 vs. Figure 5C ) and correspondingly, fewer genes were modified in LGG vs. normal. Of those 259 EC-enriched genes that were modified in LGG, parallels were observed with GBM e.g. 260 MYO1B, DLL4, FOXS1, GPR4, LLRC32, TM4SF18 'gained' EC-enrichment and SDPR, 261 FAM111A, PGR, ANXA3, GATA2 'lost' EC-enrichment, in both tumour grades ( Figure 5C and was highly abundant in GBM EC (green arrows indicate positive staining). Similar 279 patterns were observed for CD93 (receptor for the C1q complement factor) ( Figure 6Aii ) and 280 ANGPT2 (angiopoietin 2) ( Figure 6Aiii ). 281
When transcripts were classified as EC-enriched in normal brain, but not in GBM ( Figure 5C , 282 green data points), this could indicate that: (1) expression was lost from GBM EC, or (2) 283 expression was gained outside the vasculature i.e. in tumour tissue (illustrated in Figure 7A  284 and B). ANXA3 (Annexin 3A) was EC-enriched in normal brain, but not in GBM (mean corr. 285 0.66 normal vs. -0.09 GBM) and ANXA3 mRNA was decreased in GBM vs. normal (mean 286 TPM 1.6 GBM vs. 10.3 normal p<0.0001) ( Figure 6Bi ). IHC showed ANXA3 was expressed 287 in normal EC, was variable in LGG EC, and was absent from GBM EC. Similar patterns were 288 observed for PRX (Periaxin) ( Figure 6Bii ) and ABCB1 (ATP-binding cassette sub-family B 289 member 1) ( Figure 6Biii ). CAV2 (Caveolin 2) was also EC-enriched in normal brain, but not 290 GBM (mean corr. 0.52 normal vs. 0.16 GBM) ( Figure 6Ci ) however, CAV2 mRNA was 291 increased in GBM vs. normal (mean TPM 20.9 GBM vs. 7.1 normal p<0.0001), and CAV2 292 was expressed outside the EC compartment ( Figure 6Ci ). Similar was observed for A2M 293 ( Figure 6Cii ) and HLA-B (Figure 6Ciii ). Generally, LGG represented an 'intermediate state' 294 between normal brain and GBM, the degree of similarity to either condition depending on the 295 specific transcript. 296
We identified 10 GBM EC markers ( Figure 7C ), based on the following criteria: [1] they were 297 not expressed in EC from multiple other vascular beds (Butler et al., 2016) [2] they had low 298 expression levels in the normal brain (mean TPM<5) [3] they had a high differential EC-299 enriched correlation between GBM and normal ( Table 1 ). The 10 GBM-EC markers 300 correlated with each other in the GBM RNAseq ( Figure 7D ), but not the normal RNASeq 301 (mean corr. GBM 0.61 ± 0.06 vs. normal 0.18 ± 0.05). Consistent with previous observations, 302
LGG represented an intermediate between GBM and normal (mean corr. LGG 0.46 ± 0.04) 303 (correlation matrices, Table S7 , Tab 4). All 10 GBM-EC markers were also in the EC-304 annotated groups in the WGCNA of the GBM RNAseq ( Figure 7E, Figure S6 ), consistent 305 with co-expression in GBM EC. Thus, our method can be applied to perform a systems-306 13 based identification of highly GBM-specific EC-markers, that could have clinical applications 307 for tumour grading, prognosis prediction and therapeutic targetting. 308 309 14
DISCUSSION 310
We have demonstrated that publically available expression data can be used, in combination 311 with our method, to provide a road map of cell type-enriched transcripts in the human brain, 312 and to provide an unprecedented resolution of the changes in the EC-enriched transcriptome 313 associated with glioblastoma multiforme (GBM) and lower grade glioma (LGG). We provide 314 searchable tables (Table S2- , 326 2014; Saliba et al., 2014) . As sample collection and processing needs to be tightly controlled, 327 many brain scRNAseq studies use non-human tissue, e.g. (Pandey et al., 2018; Rosenberg 328 et al., 2018; Vanlandewijck et al., 2018) . In contrast, our method can be used to analyse 329 hundreds of human biological replicates concurrently, extracting information from bulk 330 RNAseq data, from normal or diseased tissue. Results can be directly compared across 331 datasets, regardless of processing or analysis platforms, at no experimental expense. 332
However, our analysis does have limitations; we applied strict thresholds to maximise 333 confidence in our classifications and to only identify the most highly specific genes for each 334 cell type. It was not feasible to identify an extensive panel of transcripts expressed at 335 moderately higher levels in one cell type vs. others, which is reflected by the comparatively 336 low number of genes we annotated as cell-enriched, compared to isolated brain cell type or 337 15 scRNAseq studies (Darmanis et al., 2015; Vanlandewijck et al., 2018; Zhang et al., 2014) . A 338 further limitation is the possible incorrect classification of transcripts, particularly between 339 closely associated cell types, which could have comparable ratios across samples, such as 340 EC with pericytes or smooth muscle cells (SMC). We used test-panels to exclude SMC as a 341 source of false positive EC-enriched genes, but equivalent analysis for pericytes was more 342 challenging, due to a lack of specific markers (Armulik et al., 2011). However, genes 343 , 2015) . We 360 identified transcripts enriched in normal brain EC, but not in GBM EC, including those 361 encoding for specialised brain EC proteins, such as the drug efflux pump TP-binding 362 cassette sub-family B member 1 (ABCB1) (Borst and Schinkel, 2013) , and the immuno-and 363 permeability regulatory protein Periaxin (PRX) (Wang et al., 2018) . As specialised brain EC 364 features are induced and regulated by the local microenvironment (Chow and Gu, 2015) and 365 16 rapidly lost ex vivo (Urich et al., 2012; Wilhelm et al., 2011) one could speculate that GBM 366 EC fail to express such genes due to the loss of the normal microenvironment. The majority 367 of transcripts we identified as having EC-specific expression in both normal and GBM were 368 'core' EC genes, found throughout human tissue beds (Butler et al., 2016) ; suggesting GBM 369 EC maintain critical genes for basic identify and function. 370
We identified a panel of GBM EC markers, some of which have been previously reported, 371
including CD93 (Dieterich et al., 2012; Langenkamp et al., 2015) and ANGPT2 (Dieterich et 372 al., 2012; Scholz et al., 2016; Stratmann et al., 1998) . The majority, to our knowledge, were 373 previously unknown, e.g. exocyst complex component 3-like 2 (EXOC3L2), TNF receptor 374 superfamily member 4 (TNFRSF4), Thromboxane A2 Receptor (TBXA2R) and Prostaglandin 375 I2 Receptor (PTGIR). EXOC3L2, a component of the exocyst involved in vesicle fusion with 376 the plasma membrane, is poorly characterised; the only published study on the protein 377 describes its upregulation in mouse embryonic sprouting blood vessels and induction in 378 primary human cells in response to VEGF (Barkefors et al., 2011) . This is consistent with its 379 expression in GBM EC; GBM tumour cells produce VEGF, which induces angiogenesis (Das 380 and Marsden, 2013) , however, the role of EXOC3L2, or potential as angiogenic target in 381 GBM remains unknown. TNFRSF4 (Ox40) has been a target of experimental tumour 382 immunotherapy, including in glioma, due to its expression on tumour infiltrating T-cells 383 (Buchan et al., 2018) . In a mouse sarcoma model, TNFRSF4 was also expressed on EC 384 which, following TNFRSF4-agonist treatment, responded with (T-cell independent) VCAM-1 385 expression (Pardee et al., 2010) . Thus, one could speculate that TNFRSF4 expression on 386 GBM EC could indicate a role for a direct EC-interaction in the antitumor effect of TNFRSF4-387 targeted immunotherapy (Curry et al., 2016) . TBXA2R and PTGIR encode for prostaglandin 388 receptors, which bind thromboxane A2 and prostacyclin, respectively, products of the short 389 astrocytoma tumour cells express ATR1, compared to lower grade, and expression is 408 associated with cell proliferation, vascularisation and shorter survival (Arrieta et al., 2008) . 409
Angiotensin II induces NOX4, which regulates the production of reactive oxygen species 410 (ROS) (Nguyen Dinh Cat et al., 2013) . ROS play an important role in signal transduction, cell 411 differentiation, tumour cell proliferation, apoptosis and angiogenesis (Guo and Chen, 2015) . 412 NOX4 is more highly expressed in GBM than lower grade tumours, with a role in tumour 413 proliferation and resistance to apoptosis induced by chemotherapeutic agents (Shono et al., 414 2008) . Despite the acknowledged importance of RAS in cancer, the specific cell types 415 underlying the increased signalling are not well described. Based on our data, we speculate 416 that GBM EC drive increased local levels of angiotensin II and II, which promote cancer 417 progression and maintenance. 418
In summary, we identify cell-enriched genes from unfractionated brain RNAseq, without the 419 need for high-level bioinformatics expertise or complex modelling. We model system-level 420 18 changes in the EC-compartment associated with brain malignancy of increasing severity, 421 providing biological insight and identifying potential targets for therapy. 422 RNAseq of isolated human and mouse brain cell types (Zhang et al., 2014; Zhang et al., 441 2016) were downloaded from the Gene Expression Omnibus (GEO) database (Accession 442 IDs: GSE67835, GSE73721 and GSE52564, respectively). Comparative transcript 443 expression between normal, LGG and GBM samples were downloaded from the OASIS 444 portal (oasis-genomics.org) (Fernandez-Banet et al., 2016) . 445
METHODS AND RESOURCES

EXPERIMENTAL METHODS 446
Tissue Profiling: Human tissue sections 447 Tissue sections from human cerebral cortex were generated and stained, as previously 448 described (Ponten et al., 2008; Uhlen et al., 2015) . Briefly, formalin fixed and paraffin 449 embedded tissue samples were sectioned, de-paraffinised in xylene, hydrated in graded 450 20 alcohols and blocked for endogenous peroxidase in 0.3% hydrogen peroxide diluted in 95% 451 ethanol. For antigen retrieval, a Decloaking chamber® (Biocare Medical, CA) was used. 452
Slides were boiled in Citrate buffer®, pH6 (Lab Vision, CA). Primary antibodies and a dextran 453 polymer visualization system (UltraVision LP HRP polymer®, Lab Vision) were incubated for 454 30 min each at room temperature and slides were developed for 10 minutes using 455
Diaminobenzidine ( 
QUANTIFICATION AND STATISTICAL ANALYSIS
472
Reference transcript based correlation analysis 473
This method was adapted from that previously developed to determine the cross-tissue pan-474 EC-enriched transcriptome (Butler et al., 2016) . As different cell types are present in different 475 proportions across individual samples, we used a correlation analysis to identify cell-type 476 specific transcripts. We calculated the pairwise Spearman correlation coefficients between 477 reference transcripts selected as proxy markers for: endothelial cells ( 
Weighted correlation network (WGCNA) analysis 492
The R package WGCNA was used to perform co-expression network analysis for gene 493 clustering, on log2 expression values. The analysis was performed according to 494 recommendations in the WGCNA manual. Genes with too many missing values were 495 excluded using the goodSamplesGenes() function. The remaining genes were used to 496 cluster the samples, and obvious outlier samples were excluded. Using these genes and 497 samples a soft-thresholding power was selected and the networks were constructed using a 498 minimum module size of 15 and merging threshold of 0.05. Eigengenes were calculates from 499 the resulting clusters and eigengene dendrograms were constructed using the 500 plotEigengeneNetworks() function. 501
Brain single-cell and isolated cell fraction RNAseq datasets 502
Brain cell type expression datasets from scRNAseq (Darmanis et al., 2015) (GSE67835) and 503 isolated cell type RNAseq (Zhang et al., 2014; Zhang et al., 2016) (GSE73721 and  504 GSE52564) studies were used to calculate cell type specific enrichment values for each 505 mapped transcript. For scRNAseq cell-type enrichment was calculated using the ROTS 506 22 analysis method (Suomi et al., 2017) and enrichment was defined as ROTS score >2. For 507 the isolated cell type RNAseq fold-enrichment values in each cell type: EC, AC, OC 508 (myelinating oligodendrocytes and newly formed oligodendrocytes were combined), NC and 509 MG were calculated as described in the original studies; 'FPKM expression in one cell type 510 divided by the average expression level in all other cell types'. Cell enrichment was defined 511 as a fold-enrichment of >2. 512
Gene Ontology (GO) Enrichment analysis 513
The Gene Ontology Consortium (Ashburner et al., 2000) and PANTHER classification 514 resource (Mi et al., 2013; Mi et al., 2016) were used to identify over represented terms 515 (biological processes) in the panel of identified cell-type-enriched transcripts from the GO 516 ontology database (release date March 2016). 517
ADDITIONAL RESOURCES 518
The Human Protein Atlas (HPA) website contains details of all antibody-based protein 519 profiling used in this study: www.proteinatlas.org. A searchable web-based interface can be 520 used to explore the datasets presented here, on a transcript-by-transcript basis 521 
